Sponsorship Opportunities
What is the future of CAR-T cell
therapy?
16–17 June, 2026
Join a hand-picked group of industry leaders at the inaugural Cell & Gene Therapy Insights Special Interest Group.
The Cell & Gene Therapy Insights Special Interest Group (SIG) brings together leading experts from across the CAR-T ecosystem to address one of the sector’s most urgent and timely questions: what comes next for CAR-T cell therapy? This invitation-only initiative provides a trusted, collaborative forum for open discussion and actionable problem-solving - building consensus, defining priorities, and driving meaningful progress for the field.
UPCOMING EVENT
WEBINAR
What is the Future of CAR-T Cell Therapy? - Cell & Gene Therapy Insights SIG 2026
Join a hand-picked group of industry leaders at the inaugural Cell & Gene Therapy Insights Special Interest Group.
The Cell & Gene Therapy Insights Special Interest Group (SIG) brings together leading experts from across the CAR-T ecosystem to address one of the sector’s most urgent and timely questions: what comes next for CAR-T cell therapy? This invitation-only initiative provides a trusted, collaborative forum for open discussion and actionable problem-solving - building consensus, defining priorities, and driving meaningful progress for the field.
What this is
An invitation-only SIG bringing together senior decision-makers from pharma, biotech, regulators, clinicians, payers and academia to define what comes next for CAR-T.
This is not a broadcast event. It is a closed door, three-day working forum held under Chatham House Rules, designed for candid discussion, practical problem-solving and consensus building.
Outputs include:
• A high-impact White Paper outlining agreed priorities, solutions and future direction
• Strategic recommendations spanning R&D, manufacturing and access
• Ongoing content activation (webinars, progress reports, infographics) to extend reach and reinforce key themes
• Positioning across Cell & Gene Therapy Insights’ 41,000-strong registered audience of industry professionals
This SIG will become a defining reference point for the CAR-T community in 2026.
Why this matters now
After a decade of momentum, CAR-T stands at a strategic inflection point:
• Autologous models remain constrained by cost, complexity, and scalability
• Allogeneic approaches have yet to deliver on early expectations
• Advances in manufacturing, analytics, gene editing, and in vivo approaches are reshaping the landscape
• Emerging applications, including autoimmune indications, are expanding the opportunity
This SIG will clarify where genuine progress will come from — and what industry must prioritize next.
Sponsorship & thought leadership involvement
Each working group is available for exclusive sponsorship.
This is designed for organizations that want to be visibly aligned with progress — not simply present alongside competitors.
Sponsors receive:
• Category exclusivity within the working group
• Direct participation for a senior subject matter expert, shaping discussion and recommendations
• Prominent association with the White Paper and all subsequent content
• Opportunity to exclusively host a webinar or other market facing piece based on the discussion to drive awareness and lead generation
• High-quality lead engagement driven by targeted activation across our industry audience
There are no exhibition stands. No long delegate lists. No generic branding placements.
This is strategic positioning at the centre of a focused, senior-level discussion that will influence how the market thinks about CAR-T in 2026 and beyond.
Steering Committee
Meet our Cell & Gene Therapy Insights SIG Steering Committee Members
FAQs
Who can participate in the SIG?
Participation is by invitation only and aimed at senior experts and thought leaders from across the CAR-T cell therapy community. If you’re interested in contributing, you can register your interest to be considered.
When and where will the SIG take place?
The Cell & Gene Therapy Insights SIG will take place virtually on June 16-17, 2026, bringing together up to 60 selected participants from across the globe.
What happens after the meeting?
Initially, the discussion outcomes will be transformed into a White Paper, reports, and other open-access resources, ensuring the insights and strategies developed by the group have a lasting impact across the sector. Looking further ahead, additional activities and content may include webinars, articles, and in-person SIG member functions and report-outs to the attendees at major global conferences for the cell & gene therapy sector.